Brief: FDA Broadens Access To Over-The-Counter Naloxone Nasal Spray For Opioid Overdose
16/06/2026 13:50
BRIEF-FDA Broadens Access To Over-The-Counter Naloxone Nasal Spray For Opioid Overdose June 16 (Reuters) - Amphastar Pharmaceuticals, Inc AMPH.O:
FDA BROADENS ACCESS TO OVER-THE-COUNTER NALOXONE NASAL SPRAY FOR OPIOID OVERDOSE
FDA: APPROVED OTC INTRANASAL NALOXONE PRODUCT, REXTOVY, A 4 MG NALOXONE HYDROCHLORIDE NASAL SPRAY FOR EMERGENCY TREATMENT OF OPIOID OVERDOSE
Source text: [ID:]
Further company coverage: AMPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amphastar Pharmaceuticals
See all newsAmphastar Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Amphastar Pharmaceuticals Q2 EPS USD 0.67
U.S. STOCKS ON THE MOVE-RBB Bancorp, Roblox, Open Lending
U.S. STOCKS ON THE MOVE-Amkor Technology, Dynatrace, Corvex
Amphastar rises after FDA approves new over-the-counter overdose spray